Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.615
Neutral
RSI(14)
40.375
Neutral
STOCH(KDJ)(9,3,3)
64.110
Buy
ATR(14)
0.753
High Vlolatility
CCI(14)
45.172
Neutral
Williams %R
43.610
Buy
TRIX(12,20)
-0.898
Sell
StochRSI(14)
86.092
Overbought
Zai Lab Ltd
ZLAB18.330USD
-0.250-1.35%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.03BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Zai Lab Ltd
Currency: USD Updated: 2025-12-26Key Insights
Zai Lab Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 72/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.85.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zai Lab Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
47.852
Target Price
+151.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Zai Lab Ltd Highlights
StrengthsRisks
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 85.54% year-on-year.
Fairly Valued
The company’s latest PE is -9.40, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 46.61M shares, decreasing 24.80% quarter-over-quarter.
Held by Sarah Ketterer
Star Investor Sarah Ketterer holds 50.91K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.33.
Financial Health
Currency: USD Updated: 2025-12-26The current financial score of Zai Lab Ltd is 8.47, ranking 64/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 116.09M, representing a year-over-year increase of 13.52%, while its net profit experienced a year-over-year increase of 13.70%.
Score
Financials
9.17
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.78
Operational Efficiency
10.00
Growth Potential
8.06
Shareholder Returns
7.32
Zai Lab Ltd's Company Valuation
Currency: USD Updated: 2025-12-26The current valuation score of Zai Lab Ltd is 7.41, ranking 72/158 in the Pharmaceuticals industry. Its current P/E ratio is -9.40, which is -58.33% below the recent high of -3.92 and -110.45% above the recent low of -19.79.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 72/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-26The current earnings forecast score of Zai Lab Ltd is 8.36, ranking 40/158 in the Pharmaceuticals industry. The average price target for Zai Lab Ltd is 48.00, with a high of 67.22 and a low of 23.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
47.852
Target Price
+151.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Zai Lab Ltd
ZLAB
11
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-26The current price momentum score of Zai Lab Ltd is 6.61, ranking 114/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 20.26 and the support level at 16.61, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
18.028
Buy
MA10
17.665
Buy
MA20
18.476
Sell
MA50
21.807
Sell
MA100
27.402
Sell
MA200
30.813
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-26The current institutional shareholding score of Zai Lab Ltd is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 41.70%, representing a quarter-over-quarter decrease of 22.99%. The largest institutional shareholder is Ron Baron, holding a total of 1.37M shares, representing 1.22% of shares outstanding, with 26.14% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Capital World Investors
Fidelity Management & Research Company LLC
ClearBridge Investments, LLC
RTW Investments L.P.
Janus Henderson Investors
Wellington Management Company, LLP
Frazier Life Sciences Management, L.P.
Segantii Capital Management Limited
Qiming Venture Partners
1
2
Risk Assessment
Currency: USD Updated: 2025-12-26The current risk assessment score of Zai Lab Ltd is 4.98, ranking 79/158 in the Pharmaceuticals industry. The company's beta value is 0.82. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.82
VaR
+6.95%
240-Day Maximum Drawdown
+60.49%
240-Day Volatility
+66.38%
Return
Best Daily Return
60 days
+6.29%
120 days
+14.37%
5 years
+41.80%
Worst Daily Return
60 days
-7.52%
120 days
-11.98%
5 years
-20.31%
Sharpe Ratio
60 days
-5.92
120 days
-2.25
5 years
-0.17
Risk Assessment
Maximum Drawdown
240 days
+60.49%
3 years
+66.46%
5 years
+92.38%
Return-to-Drawdown Ratio
240 days
-0.45
3 years
-0.27
5 years
-0.19
Skewness
240 days
+0.69
3 years
+0.78
5 years
+1.16
Volatility
Realised Volatility
240 days
+66.38%
5 years
+77.93%
Standardised True Range
240 days
+8.53%
5 years
+15.55%
Downside Risk-Adjusted Return
120 days
-326.92%
240 days
-326.92%
Maximum Daily Upside Volatility
60 days
+36.72%
Maximum Daily Downside Volatility
60 days
+43.24%
Liquidity
Average Turnover Rate
60 days
+0.07%
120 days
+0.09%
5 years
--
Turnover Deviation
20 days
-33.12%
60 days
-4.22%
120 days
+18.93%
Peer Comparison
Pharmaceuticals
Zai Lab Ltd
ZLAB
7.02 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Zai Lab Ltd?
The TradingKey Stock Score provides a comprehensive assessment of Zai Lab Ltd based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Zai Lab Ltd’s performance and outlook.
How do we generate the financial health score of Zai Lab Ltd?
To generate the financial health score of Zai Lab Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Zai Lab Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Zai Lab Ltd.
How do we generate the company valuation score of Zai Lab Ltd?
To generate the company valuation score of Zai Lab Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Zai Lab Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Zai Lab Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Zai Lab Ltd.
How do we generate the earnings forecast score of Zai Lab Ltd?
To calculate the earnings forecast score of Zai Lab Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Zai Lab Ltd’s future.
How do we generate the price momentum score of Zai Lab Ltd?
When generating the price momentum score for Zai Lab Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Zai Lab Ltd’s prices. A higher score indicates a more stable short-term price trend for Zai Lab Ltd.
How do we generate the institutional confidence score of Zai Lab Ltd?
To generate the institutional confidence score of Zai Lab Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Zai Lab Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Zai Lab Ltd.
How do we generate the risk management score of Zai Lab Ltd?
To assess the risk management score of Zai Lab Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Zai Lab Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Zai Lab Ltd.
